RealSeq Biosciences Awarded NIH SBIR Phase II Grant to Advance Breakthrough RNA Fragmentomics Platform
ANTA CRUZ, CA, UNITED STATES, September 17, 2025 /EINPresswire.com/ — RealSeq Biosciences, a pioneer in RNA-based diagnostics, today announced it has received a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) (FAIN# R44HG013284; Federal Award Date: August 15, 2025). This highly competitive award provides multi-year, non-dilutive funding to accelerate development and commercialization of RealSeq’s proprietary RNA fragmentomics platform—RiboMarker a next-generation technology poised to transform disease diagnostics and biomarker discovery.
The award follows the successful completion of RealSeq’s Phase I program, where the company demonstrated the power of RNA fragmentomics to uncover previously invisible disease signatures in liquid biopsy samples. Phase II funding will enable RealSeq to:
- Advance assay development for several applications including oncology and infectious disease.
- Expand partnerships with leading commercial, clinical and academic institutions.
- Prepare the platform for commercial launch and regulatory engagement.
